Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
New York Times
NYT
$10.3B
| $182M | 0.14% |
5,645,686
+304,776
| +6% | +$9.47M |
|
152
AB InBev
BUD
$159B
| $181M | 0.14% |
2,209,976
+161,076
| +8% | +$13.4M |
|
153
Fortis
FTS
$28.6B
| $180M | 0.14% |
4,332,905
+466,005
| +12% | +$19.1M |
|
154
Douglas Emmett
DEI
$1.92B
| $180M | 0.14% |
4,094,936
-746,864
| -15% | -$32.3M |
|
155
Enbridge
ENB
$113B
| $180M | 0.14% |
4,519,728
+974,304
| +27% | +$36.4M |
|
156
CenterPoint Energy
CNP
$26.5B
| $179M | 0.14% |
6,558,680
+1,598,180
| +32% | +$43.5M |
|
157
Las Vegas Sands
LVS
$29.6B
| $178M | 0.14% |
2,583,934
-737,700
| -22% | -$46M |
|
158
Tenaris
TS
$27B
| $176M | 0.13% |
7,751,800
+2,711,800
| +54% | +$58.3M |
|
|
CZR
159
DELISTED
Caesars Entertainment Corporation
CZR
| $173M | 0.13% |
12,697,715
+6,095,830
| +92% | +$77.2M |
|
160
Petrobras Class A
PBR.A
$103B
| $171M | 0.13% |
11,473,599
+5,343,699
| +87% | +$75.7M |
|
161
AutoZone
AZO
$49.7B
| $170M | 0.13% |
142,900
-27,900
| -16% | -$32.2M |
|
|
ECHO
162
EchoStar
ECHO
$25.6B
| $169M | 0.13% |
3,912,448
-108,932
| -3% | -$4.37M |
|
163
Lamar Advertising Co
LAMR
$15.6B
| $169M | 0.13% |
1,890,591
-71,209
| -4% | -$5.96M |
|
164
Rogers Communications
RCI
$19.1B
| $169M | 0.13% |
3,393,483
-639,800
| -16% | -$30.8M |
|
165
Copa Holdings
CPA
$5.49B
| $168M | 0.13% |
1,554,761
+293,675
| +23% | +$30.6M |
|
166
Visa
V
$677B
| $168M | 0.13% |
893,500
+843,400
| +1,683% | +$152M |
|
167
Idexx Laboratories
IDXX
$46.2B
| $167M | 0.13% |
639,929
+12,804
| +2% | +$3.37M |
|
168
Telus
TU
$15.2B
| $167M | 0.13% |
8,622,800
-2,188,200
| -20% | -$40.5M |
|
|
SAFM
169
DELISTED
Sanderson Farms Inc
SAFM
| $165M | 0.13% |
939,117
-7,700
| -0.8% | -$1.22M |
|
170
SL Green Realty
SLG
$3.95B
| $164M | 0.13% |
1,844,709
+206,604
| +13% | +$17M |
|
171
Snap
SNAP
$9.32B
| $163M | 0.12% |
9,951,900
+7,994,000
| +408% | +$118M |
|
172
Clean Harbors
CLH
$16.4B
| $161M | 0.12% |
1,877,635
+106,633
| +6% | +$8.67M |
|
|
CEO
173
DELISTED
CNOOC Limited
CEO
| $159M | 0.12% |
953,839
+131,097
| +16% | +$20.1M |
|
174
RenaissanceRe
RNR
$13.2B
| $157M | 0.12% |
802,415
-111,700
| -12% | -$21.2M |
|
|
CS
175
DELISTED
Credit Suisse Group
CS
| $156M | 0.12% |
11,616,496
+376,000
| +3% | +$4.81M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.